Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy

 
• By Mandy Jackson

Celgene will pay $9bn to buy the 90.3% of Juno that it doesn't already own, seeking to not only become a leader in the CAR-T field, but to increase its leadership in non-Hodgkin lymphoma, multiple myeloma, other hematological malignancies.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

More from Deals

More from Business